Evidence map›Paper›PMID 19641164›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2009

Determination of adenosine A1 receptor agonist and antagonist pharmacology using Saccharomyces cerevisiae: implications for ligand screening and functional selectivity.

Gregory D Stewart, Celine Valant, Simon J Dowell, Dalibor Mijaljica, Rodney J Devenish, Peter J Scammells, Patrick M Sexton, Arthur Christopoulos

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Functional Expression of Adenosine AInternational journal of molecular sciences · 2020
    Article
  7. Article
  8. Rules of Engagement: GPCRs and G Proteins.ACS pharmacology & translational science · 2018
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist.Proceedings of the National Academy of Sciences of the United States of America · 2014
    Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Gregory D StewartMonash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.
Celine Valant
Simon J Dowell
Dalibor Mijaljica
Rodney J Devenish
Peter J Scammells
Patrick M Sexton
Arthur Christopoulos
Monash University · AUGlaxoSmithKline (Australia) · AUInstitute of Medicinal Plant Development · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The budding yeast, Saccharomyces cerevisiae, is a convenient system for coupling heterologous G protein-coupled receptors (GPCRs) to the pheromone response pathway to facilitate empirical ligand screening and/or GPCR mutagenesis studies. However, few studies have applied this system to define GPCR-G protein-coupling preferences and furnish information on ligand affinities, efficacies, and functional selectivity. We thus used different S. cerevisiae strains, each expressing a specific human Galpha/yeast Gpa1 protein chimera, and determined the pharmacology of various ligands of the coexpressed human adenosine A(1) receptor. These assays, in conjunction with the application of quantitative models of agonism and antagonism, revealed that (-)-N(6)-(2-phenylisopropyl)adenosine was a high-efficacy agonist that selectively coupled to Gpa/1Galpha(o), Gpa1/Galpha(i1/2), and Gpa1/Galpha(i3), whereas the novel compound, 5'-deoxy-N(6)-(endo-norborn-2-yl)-5'-(2-fluorophenylthio)adenosine (VCP-189), was a lower-efficacy agonist that selectively coupled to Gpa1/Galpha(i) proteins; the latter finding suggested that VCP-189 might be functionally selective. The affinity of the antagonist, 8-cyclopentyl-1,3-dipropylxanthine, was also determined at the various strains. Subsequent experiments performed in mammalian Chinese hamster ovary cells monitoring cAMP formation/inhibition, intracellular calcium mobilization, phosphorylation of extracellular signal-regulated kinase 1 and 2 or (35)S-labeled guanosine 5'-(gamma-thio)triphosphate binding, were in general agreement with the yeast data regarding agonist efficacy estimation and antagonist affinity estimation, but revealed that the apparent functional selectivity of VCP-189 could be explained by differences in stimulus-response coupling between yeast and mammalian cells. Our results suggest that this yeast system is a useful tool for quantifying ligand affinity and relative efficacy, but it may lack the sensitivity required to detect functional selectivity of low-efficacy agonists.

Indexed as

Adenosine A1 Receptor AgonistsAdenosine A1 Receptor AntagonistsAnimalsCells, CulturedCHO CellsCricetinaeCricetulusDrug DiscoveryDrug Evaluation, PreclinicalHumansLigandsReceptor, Adenosine A1Saccharomyces cerevisiaeSignal TransductionXanthines1,3-dipropyl-8-cyclopentylxanthineAdenosine A1 Receptor AgonistsAdenosine A1 Receptor AntagonistsLigandsReceptor, Adenosine A1Xanthines

Identifiers

PMID19641164
PMCPMC2766231
OpenAlexW2011713334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.